Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
Relapsed multiple myeloma responds to combination therapy with daratumumab

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.14
Views: 2145

Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain

Prof Mateos speaks to ecancertv at ASH 2014 about the results of a phase I study on the use of daratumumab, an anti-CD38 antibody, in combination with standard approaches to treat relapsed multiple myeloma. 

Watch the press conference and read the news story for more. 



Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation